4207-54-9

Basic information

• Product Name: 5-chloro-2,2-dimethyl-pentanenitrile
• Synonyms: 5-chloro-2,2-dimethyl-pentanenitrile
• CAS NO: 4207-54-9
• Molecular Formula: C₇H₁₂ClN
• Molecular Weight: 145.63
• Mol File: 4207-54-9.mol

Chemical Properties

• Boiling Point: 227.1°Cat760mmHg
• Flash Point: 77.4°C
• Appearance: /
• Density: 0.978g/cm³
• Vapor Pressure: 0.0789mmHg at 25°C
• Refractive Index: 1.439
• CAS DataBase Reference: 5-chloro-2,2-dimethyl-pentanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-2,2-dimethyl-pentanenitrile(4207-54-9)
• EPA Substance Registry System: 5-chloro-2,2-dimethyl-pentanenitrile(4207-54-9)

Safety Data

• Hazardous Substances Data: 4207-54-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H12ClN/c1-7(2,6-9)4-3-5-8/h3-5H2,1-2H3

Upstream product

• 78-82-0 Isobutyronitrile 
• 109-70-6 1.3-chlorobromopropane 
• 50654-53-0 2-lithio-2-methylpropionitrile 
• 54305-91-8 1,4-dichloro-4-methyl-pentane 
• 7677-24-9 trimethylsilyl cyanide 
• 107-05-1 3-chloroprop-1-ene 
• 3585-33-9 lithium dimethylamide 

Downstream Products

• 56475-44-6 5-iodo-2,2-dimethylpentanenitrile 
• 4541-32-6 2,2-dimethylcyclopentanone 
• 90113-76-1 2,2-Dimethyl-5-methylsulfon-cyclopentanon 
• 1311175-59-3 methyl 4-hydroxy-3-(1-hydroxy-2,2-dimethylcyclopentyl)benzoate 
• 1142224-43-8 methyl 3-(5,5-dimethylcyclopent-1-enyl)-4-hydroxybenzoate 
• 1142224-70-1 methyl (R)-3-(2,2-dimethylcyclopentyl)-4-hydroxybenzoate 
• 1311175-77-5 methyl 3-(5,5-dimethylcyclopent-1-enyl)benzoate 
• 117705-86-9 4-<(4-cyano-4-methylpentyl)oxy>-5-ethyl-2-hydroxyacetophenone 
• 117705-89-2 1-(5-ethyl-2-hydroxy-4-((4-methyl-4-(1H-tetrazol-5-yl)pentyl)oxy)phenyl)ethanone 

Relevant articles and documents

Rate constants for the addition of the 2-cyano-2-propyl radical to alkenes in solution

Absolute rate constants for the addition of the 2-cyano-2-propyl radical to 26 alkenes CH2 = CXY at 315 K were determined in solution by time-resolved electron-spin-resonance spectroscopy. They vary with the alkene substituents from 30 M-1 s-1 to 7′010 M-1 s-1. For styrene the temperature dependence is given by log k/M-1 s-1 = 7.7 - 26.1/Θ where Θ = 2.303 RT in kJ/mol. An analysis of the substituent effects in terms of polar and enthalpic factors reveals a dominant influence of the overall reaction enthalpy.

Cascade cyclization intermolecular dipolar cycloaddition by multi-component couplings-synthesis of indolizidines and pyrrolizidines

A three-component coupling reaction of a primary amine (an amino-acid or amino-ester or hydroxylamine), an alkene or alkyne dipolarophile and an aldehyde bearing a halide as a leaving group has been developed. Condensation of the amine with the aldehyde and cyclization (intramolecular N-alkylation) provides, after decarboxylation or deprotonation, a cyclic azomethine ylide (or nitrone) that undergoes intermolecular dipolar cycloaddition with the dipolarophile. This sets up, in a single step, the bicyclic indolizidine or pyrrolizidine ring system, depending on the length of the tether between the aldehyde and the halide. The reaction is successful with stabilized and non-stabilized azomethine ylides that result from using primary amino-esters or amino-acids, respectively.

SEMICONDUCTING COMPOSITIONS COMPRISING SEMICONDUCTING POLYMERS

A semiconducting composition comprising a semiconducting polymer and a semiconducting non-polymeric polycyclic compound, wherein the semiconducting polymer comprises units of A and/or B: wherein R1, R2, R5, R6, R7, R8, x, y, p, q, r, R3, R4, R9, R10 and R11 have any of the meanings defined in the description.

ANTI-MUCUS DRUGS AND USES THEREFOR

Disclosed are methods of identifying, generating and synthesizing compounds that inhibit MAPK13 activity. In various embodiments, compounds, salts thereof and prodrugs thereof of the present teachings can be useful for the treatment of diseases and disord

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.